Current status of first- and second-line <i>Helicobacter pylori</i> eradication therapy in the metropolitan area: a multicenter study with a large number of patients

Abstract

The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients.